

REMARKS


Entry of the amendments to the specification, claims and abstract before examination of the application is respectfully requested. These claims have been amended, *inter alia*, to remove multiple dependencies.

If there are any questions regarding this Preliminary Amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket # 100878.56050US).

November 16, 2005

Respectfully submitted,


Kening Li, Ph.D.
Registration No. 44,872

Christopher T. McWhinney
Registration No. 42,875

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JFM:KLI:elew (2670935)

**POLYCLONAL ANTIBODIES, METHOD OF
PREPARATION AND USE OF SAME**

[0001] The present invention relates to polyclonal antibodies which recognize, specifically and with great affinity for, the two most important amyloid peptides, A β 40 and A β 42, as well as their use in evaluating both drugs activating the degradation of the amyloid peptides characteristic of Alzheimer's disease and drugs inhibiting their formation. In the same way, they can be useful for evaluating the activity of the enzymes involved in the processing of the precursor protein of the two amyloid peptides ~~ated~~ or the activity of the enzymes involved in the degradation of same, as well as for evaluating the level of expression of the genes involved in the entire chain of events which lead to the deposition and formation of amyloid plaques, lesions characteristic of the brains of patients suffering from Alzheimer's disease.

PRIOR ART BACKGROUND OF THE INVENTION

[0002] Certain factors are known about the biochemical and metabolic phenomena associated with the presence of Alzheimer's disease. Two morphological and histopathological changes observed in the brains of patients with Alzheimer's disease are neurofibrillar tangles (MNF) and amyloid deposits.

[0003] Intraneuronal neurofibrillar tangles are also present in other degenerative diseases but the presence of amyloid deposits both in the interneuronal spaces (neuritic plaques) and in the surrounding microvasculature (vascular plaques) seems to be characteristic of Alzheimer's disease. Of these, the neuritic plaques seem to be the most characteristic (Price, D.L. et al., Drug Development Research (1985), 5:59-68).

[0004] The main component of these amyloid plaques is a peptide of 40-42 amino acids called amyloid peptide A β 4.

[0005] Amyloid peptide A β 4 is a polypeptide produced by proteolysis from membrane glucoproteins called amyloid peptide A β 4 precursor proteins (β APP). ~~Since~~ These amyloid peptide precursor proteins are made up of 695 to 770 amino acids, ~~they and~~ are all ~~produced~~ encoded by the same gene.

[0006] Two main variants of amyloid peptide A β 4, peptide A β 40 and A β 42, with 40 and 42 amino acids respectively, have been identified which present a different tissue distribution both in physiological and in pathological conditions.

[0007] We have cloned and sequenced the β APP gene in the chicken and have shown that it is practically identical to the human gene since it produces β APPs which are highly homologous, in the order of 95%, with those of the human species, and the A β 4 peptide characteristic of Alzheimer's disease is identical to the human one. Furthermore, the chicken embryo processes β APPs in such a way that peptide A β 4 is produced, due to the action of proteolytic enzymes which cause the proteolysis of the β APPs in a key site to produce A β 4; the proteolytic enzyme which cuts β APPs to produce A β 4 is called β -secretase.

EXPLANATION DESCRIPTION OF THE INVENTION

[0008] The present invention provides polyclonal antibodies capable of specifically recognizing by means of any conventional immunological technique (western blot, immunohistochemistry, immunoprecipitation, ELISA, RIA, etc.) the presence of the amyloid peptides A β 40 and A β 42. The antibodies are obtained by immunization of mammals, preferably rabbits, with a protein conjugated with a peptide selected from a group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, optionally shortened by elimination of the amino acid radicals of the N-terminal and/or C-terminal ends, and optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein.

[0009] In a particular embodiment, the peptide corresponds to SEQ ID NO 1, optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein. In another particular embodiment, the peptide corresponds to SEQ ID NO 2, optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein. In another particular embodiment, the peptide corresponds to SEQ ID NO 3, optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein. In another particular embodiment, the peptide corresponds to SEQ ID NO 4, optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein. Though the elimination of the terminal amino acid radicals does not eliminate the specific activity, the preferred peptides are those of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4.

[0010] The provision of any of the substantially pure peptides mentioned above is also part of the present invention.

[0011] This invention also provides a method for obtaining the polyclonal antibodies mentioned above by immunization of mammals, preferably rabbits, with a protein conjugated to a peptide selected from a group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4 optionally shortened by elimination of the amino acid radicals of the N-terminal and/or C-terminal ends, and optionally lengthened by adding the appropriate amino acid radicals to conjugate the protein.

[0012] According to a preferred embodiment of the present invention, the protein used for its conjugation with the peptide is keyhole limpet hemocyanin.

[0013] In an even more preferred embodiment of the present invention, the mammals used for their immunization with the protein conjugated to the peptide are rabbits.

[0014] According to an aspect of the present invention, a new method is provided for the evaluation both of drugs activating the degradation of the amyloid peptides characteristic of

Alzheimer's disease and drugs inhibiting their production by means of the use of the polyclonal antibodies described above.

[0015] Similarly, the method also serves to evaluate the activity of the enzymes (proteases) involved in the processing of the precursor protein of the peptides cited or the activity of the enzymes involved in the degradation of same.

[0016] This invention also provides a method for the detection of the presence or absence of the amyloid peptides A β 40 and A β 42 in a specimen, using the chicken embryo or any of the extraembryonic membranes or fluids of the embryonated chicken egg as an animal test model.

[0017] According to a preferred embodiment of the present invention, a new method is provided for the evaluation both of drugs activating the degradation of the amyloid peptides characteristic of Alzheimer's disease and drugs inhibiting their production by means of the use of the chicken embryo or any of the extraembryonic membranes or fluids of the embryonated chicken egg as an animal test model.

[0018] According to another preferred embodiment of the present invention, a new method is provided for the evaluation of the activity of the enzymes (proteases) involved in the processing of the precursor protein of the peptides cited or the activity of the enzymes involved in the degradation of same by means of the use of the chicken embryo or any of the extraembryonic membranes or fluids of the embryonated chicken egg as an animal test model.

[0019] The method ~~consists~~ comprises of inoculating the drug into the embryonated chicken egg whether by simply dropping it onto the embryo itself or any of its membranes or by injecting it into the vitellus (if the embryo is young) or the vitelline sac (if the embryo is bigger), into the amniotic sac, into the allantoic sac (in embryos incubated for more than 6 days) or in the inside of the embryo itself; after adequate incubation time, the embryo and/or any of the extraembryonic membranes or fluids are extracted and the quantity of amyloid peptides

characteristic of Alzheimer's disease is analyzed by means of conventional laboratory techniques for the quantification of peptides and proteins such as western blot, immunohistochemistry, immunoprecipitation, ELISA, RIA, HPLC, etc.

EXAMPLES

[0020] The present invention is illustrated by the following examples.

EXAMPLE 1

Coupling the peptides to keyhole limpet hemocyanin (KLH)

[0021] The peptides were coupled to keyhole limpet hemocyanin via the n-terminus using the coupling agent glutaraldehyde. For this purpose the KLH protein was activated in a pH 10 borate buffer solution. The synthetic peptide was then added and the 0.3% glutaraldehyde solution was slowly added with stirring at ambient temperature. After the addition of glycine 1M to block the non-reacting glutaraldehyde, the peptide-protein conjugate was dialyzed against 3 liters of pH 8.5 borate buffer at a temperature of 4°C. The peptide-KLH conjugate was stored at 4°C.

EXAMPLE 2

Generation of polyclonal antibodies

[0022] The four polyclonal antibodies were generated by immunization of New Zealand White rabbits against the four peptides coupled to KLH which are used as an immunogen.

[0023] Each immunogen was injected into two rabbits, with five injections being performed: the first intradermic injection of the peptide-KLH conjugate in PBS and emulsified in complete Freund's adjunct and four other intramuscular ones by way of a booster dose on days 14, 28, 49 and 80 of the same peptide-KLH conjugate in PBS but this time emulsified in incomplete

Freund's adjunct, with the blood sampling being performed at 90 days to detect the presence of antibodies.

EXAMPLE 3

Purification of the antibodies by affinity

[0024] After the blood was drawn, the serum was separated and prepurified by means of desalting and the antibodies were then purified by affinity in a matrix composed of 1.5 ml of EMD epoxy-activated material (Merck) to which 5 mg of the corresponding peptide were added. The purified fractions were established in 0.1% BSA (Sigma) and stored at 4°C, with glycerol 20-50% possibly being added as a cryoprotectant.

EXAMPLE 4

Antibody titration by ELISA.

[0025] After purification by affinity, the antibody titer was determined by ELISA. For this, the antigen was placed in an ELISA Maxi Sorb plate from Nunc at a rate of 50 ng/50 µl in pH 7 PBS and the antibody was detected with donkey anti-IgG conjugated with alkaline phosphatase, using p-nitrophenyl phosphate (PNPP) in diethanolamine with 5 mM MgCl₂, pH 9.6, as a substrate and developed at 2 hours.

[0026] In conclusion, the antibodies were generated using the different synthetic peptides described above coupled with KLH. These synthetic peptides contain a very small number of amino acids, which makes them highly suitable for the chain production of homogeneous antibodies with predefined epitopes

[0027] LIST OF SEQUENCES

SEQ ID NO 1	LVFFAEDV
SEQ ID NO 2	GLMVGGVV

SEQ ID NO 3 GLMVGGVVIA
SEQ ID NO 4 RHDSGYEVHHQK

[0028] In this application the amino acids are abbreviated using the one-letter codes accepted in the field, in the form shown below:

A = Ala = alanine
C = Cys = cysteine
D = Asp = aspartic acid
E = Glu = glutamic acid
F = Phe = phenylalanine
G = Gly = glycine
H = His = histidine
I = Ile = isoleucine
K = Lys = lysine
L = Leu = leucine
M = Met = methionine
N = Asn = asparagine
P = Pro = proline
Q = Gln = glutamine
R = Arg = arginine
S = Ser = serine
T = Thr = threonine
V = Val = valine
W = Trp = tryptophan
Y = Tyr = tyrosine

[0029] The information relating to the identification of the peptide sequences described in the present invention which accompanies the present record in a form readable by computer is identical to the listing of sequences presented with the record.

[0030] NUMBER OF SEQUENCES: 4

[0031] INFORMATION ON SEQUENCE 1:

CHARACTERISTICS OF THE SEQUENCE:

LONGITUDE: 8

TYPE: amino acid

TYPE OF MOLECULE: peptide

SOURCE: Chemical Synthesis

DESCRIPTION OF THE SEQUENCE:

SEQ ID NO 1

Leu Val Phe Phe Ala Glu Asp Val

1

5

[0032] INFORMATION ON SEQUENCE 2:

CHARACTERISTICS OF THE SEQUENCE:

LONGITUDE: 8

TYPE: amino acid

TYPE OF MOLECULE: peptide

SOURCE: Chemical Synthesis

DESCRIPTION OF THE SEQUENCE:

SEQ ID NO 2

Gly Leu Met Val Gly Gly Val Val

1

5

[0033] INFORMATION ON SEQUENCE 3:

CHARACTERISTICS OF THE SEQUENCE:

LONGITUDE: 10

TYPE: amino acid

TYPE OF MOLECULE: peptide

SOURCE: Chemical Synthesis

DESCRIPTION OF THE SEQUENCE:

SEQ ID NO 3

Gly Leu Met Val Gly Gly Val Val Ile Ala

1

5

10

[0034] INFORMATION ON SEQUENCE 4:

CHARACTERISTICS OF THE SEQUENCE:

LONGITUDE: 12

TYPE: amino acid

TYPE OF MOLECULE: peptide

SOURCE: Chemical Synthesis

DESCRIPTION OF THE SEQUENCE:

SEQ ID NO 4

Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

1

5

10

CLAIMS

1. Polyclonal antibodies for the specific recognition of the main forms of amyloid beta peptide, A β 40 and A β 42, obtainable by immunization of mammals with a protein conjugated to a peptide selected from the group formed by:
 - the peptide of SEQ ID NO 1, the peptide of SEQ ID NO 2, the peptide of SEQ ID NO 3, the peptide of SEQ ID NO 4;
 - the peptides with a sequence resulting from eliminating the N-terminal and/or C-terminal amino acid radicals of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or SEQ ID NO 4;
 - and the peptides resulting from adding to any of the preceding sequences the amino acid radicals necessary for the conjugation of the protein.
2. Polyclonal antibody according to claim 1, characterized in that the immunization is performed with a peptide selected from the group formed by:
 - the peptide of SEQ ID NO 1;
 - the peptides with a sequence resulting from eliminating the N-terminal and/or C-terminal amino acid radicals of SEQ ID NO 1;
 - and the peptides resulting from adding to any of the preceding sequences the amino acid radicals necessary for the conjugation of the protein.
3. Polyclonal antibody according to claim 1, characterized in that the immunization is performed with a peptide selected from the group formed by:
 - the peptide of SEQ ID NO 2;
 - the peptides with a sequence resulting from eliminating the N-terminal and/or C-terminal amino acid radicals of SEQ ID NO 2;

- and the peptides resulting from adding to any of the preceding sequences the amino acid radicals necessary for the conjugation of the protein.
4. Polyclonal antibody according to claim 1, characterized in that the immunization is performed with a peptide selected from the group formed by:
- the peptide of SEQ ID NO 3;
 - the peptides with a sequence resulting from eliminating the N-terminal and/or C-terminal amino acid radicals of SEQ ID NO 3;
 - and the peptides resulting from adding to any of the preceding sequences the amino acid radicals necessary for the conjugation of the protein.
5. Polyclonal antibody according to claim 1, characterized in that the immunization is performed with a peptide selected from the group formed by:
- the peptide of SEQ ID NO 4;
 - the peptides with a sequence resulting from eliminating the N-terminal and/or C-terminal amino acid radicals of SEQ ID NO 4;
 - and the peptides resulting from adding to any of the preceding sequences the amino acid radicals necessary for the conjugation of the protein.
6. Polyclonal antibody according to any of the above claims 1 through 5, characterized in that the protein is keyhole limpet hemocyanin (KLH).
7. Polyclonal antibody according to any of the above claims 1 through 6, characterized in that the mammals are rabbits.
8. Substantially pure peptide, characterized in that it holds a sequence of amino acids selected from the group defined in claim 1.

9. Peptide according to claim 8, characterized in that the sequence is selected from the group defined in claim 2.
10. Peptide according to claim 9, characterized in that the sequence is SEQ ID NO 1.
11. Peptide according to claim 8, characterized in that the sequence is selected from the group defined in claim 3.
12. Peptide according to claim 11, characterized in that the sequence is SEQ ID NO 2.
13. Peptide according to claim 8, characterized in that the sequence is selected from the group defined in claim 4.
14. Peptide according to claim 13, characterized in that the sequence is SEQ ID NO 3.
15. Peptide according to claim 8, characterized in that the sequence is selected from the group defined in claim 5.
16. Peptide according to claim 15, characterized in that the sequence is SEQ ID NO 4.
17. Use of a peptide according to any of the preceding claims 8 through 16 to obtain polyclonal antibodies by means of conjugation to a protein and immunization of mammals.
18. Use according to claim 17, characterized in that the protein is keyhole limpet hemocyanin (KLH).
19. Use according to either of the preceding claims 17 or 18, characterized in that the mammals are rabbits.
20. Method for obtaining polyclonal antibodies for the specific recognition of the main forms of amyloid beta peptide, A β 40 and A β 42, characterized in that mammals are immunized with a protein conjugated to a peptide selected from the group defined in claim 1.
21. Method according to claim 20, characterized in that the protein used is keyhole limpet hemocyanin (KLH).
22. Method according to either of the preceding claims 20 or 21, characterized in that the mammals are rabbits.

23. Method of detecting the presence or absence of amyloid peptides A β 40 and A β 42 in a specimen, characterized in that it includes placing said specimen in contact with an antibody defined as in claim 1, and detecting the presence or absence of the complex formed by said amyloid peptides and said antibody.
24. Method of evaluating both drugs activating the degradation of the amyloid peptides and the drugs inhibiting their production, by means of the use of the polyclonal antibodies described in claim 1, characterized in that the embryonated egg of the chicken is used as an animal test model.
25. Use of the embryonated chicken egg as an animal test model to evaluate both the drugs activating the degradation of the amyloid peptides and the drugs inhibiting their production, by means of the use of polyclonal antibodies as markers of the presence or absence of said amyloid peptides.
26. Use according to claim 25, characterized in that the polyclonal antibodies used are those defined in claim 1.

LIST OF SEQUENCES

<110> University of Saragosa
<120> Polyclonal antibodies, method of preparation and use of same
<130>
<160> 4
<170> Patent In version 3.1

<210> 1
<211> 8
<212> PRT
<213> Chemical Synthesis
<220>
<221> PEPTIDE
<222> (1) .. (8)
<223>
<400> 1

Leu Val Phe Phe Ala Glu Asp Val
1 5

<210> 2
<211> 8
<212> PRT
<213> Chemical Synthesis
<220>
<221> PEPTIDE
<222> (1) .. (8)
<223>
<400> 2

Gly Leu Met Val Gly Gly Val Val
1 5

<210> 3
<211> 10
<212> PRT
<213> Chemical Synthesis
<220>
<221> PEPTIDE
<222> (1) .. (10)
<223>
<400> 3

Gly Leu Met Val Gly Gly Val Val Ile Ala
1 5 10

<210> 4
<211> 12
<212> PRT
<213> Chemical Synthesis
<220>
<221> PEPTIDE
<222> (1) .. (12)
<223>
<400> 4

Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys
1				5				10			